Aim: The BNP biomarker application optimization for myocardial dysfunction diagnosis in men citizens of Podillia region in Ukraine with uncomplicated essential hypertension and left ventricular hypertrophy by determining the plasma levels in patients with different BNP gene variants. Methods. We examined 141 men, age 40 -60 years, who live in Podillia region. Among them 62 men were diagnosed uncomplicated EH with left ventricular hypertrophy (stages 1 and 2) and CHF I-II classes according to NYHA Classification. 79 healthy men were included into the control group. The patients with uncomplicated EH and the healthy men were representative by age. The BNP (T-381C) gene polymorphism was determined by PCR, and the level of BNP plasma concentrations was established by ELISA. Results. In both healthy men and patients with uncomplicated EH with LVH, residents of Podillia region, age 40-60 years, dominates the T381C genotype and the C allele of the BNP gene. It was found that any inherited variant of the BNP gene was not associated with the risk of developing uncomplicated EH with LVH in men residents of Podillia region. However, carriers of the C381C genotype and the C allele of the BNP gene have significantly higher levels of BNP in plasma in both healthy men and patients with uncomplicated EH and LVH, residents of Podillia region, age 40-60 years. There are calculated levels of BNP that can be used for screening of large groups of people for early diagnosis of uncomplicated EH with LVH: BNP boundary level ≥ 82,41 pg/ml ables to diagnose uncomplicated EH with LVH in male carriers of the C allele heterozygote carriers of the genotypes T381C and C381C of the BNP gene; BNP boundary level ≥ 45,34 pg/ml ables to diagnose uncomplicated EH with LVH in male homozygote carriers of the T381T genotype of the BNP gene.
Introduction
In 1988 T. Sudoh, working in H. Matsuo research group, presented a peptide similar to the atrial natriuretic peptide (ANP) which was isolated from the brain of guinea pigs and called brain natriuretic peptide (BNP) [18] . Further studies showed convincingly that the main source of BNP were myocardium cells. It was demonstrated that BNP had an important pathophysiological importance in the diagnosis of heart failure (HF), risk stratification and monitoring chronic heart failure (CHF) treatment effectiveness. It is known that synthesis of BNP depends directly on left ventricule (LV) volume distension and preload pressure and is a sensitive and specific indicator of left ventricular dysfunction [3] [4] [5] 8, 14, 17, 19] .
According to the recommendations of the European Association of Cardiology (ESC, 2012) and the American College of Cardiology/American Heart Association (ACC/AHA, 2013) there were proposed boundary levels of BNP to exclude the diagnosis of acute heart failure (BNP <100 pg/ml) and CHF (BNP <35 pg/ml) and also to evaluate the CHF treatment effectiveness [12] . The employees of the Department of Internal Medicine of the Medical Faculty №2 VNPMMU have calculated the boundary level of BNP which is 50 pg/ml for screening diagnosis of isolated diastolic dysfunction of the heart when systolic function is saved [20] .
According to the global human genome data (The "Human Genome" European Community 2013) there were found 29 genic loci which are involved in the regulation of blood pressure (BP). The research of single nucleotide polymorphisms (SNPs) which also contribute to the regulation of blood pressure (the BNP gene is being considered among them as well) is still in progress. Currently the most significant BNP gene polymorphism is defined and studied. It is the physiological substitution of thymine to cytosine at the position of 381 (T-381C) also known as (SNP rs198389) which participates in the development of essential hypertension (EH) [2, 5, 7, 11, 13, [15] [16] . However, the data about the plasma level of BNP in different variants of the BNP gene polymorphism in patients with uncomplicated EH with left ventricular hypertrophy (LVH) is not numerical and has not been studied in the Ukrainian population yet at all.
The aim of the study is the BNP biomarker application optimization for myocardial dysfunction diagnosis in men residants of Podillia region in Ukraine with uncomplicated essential hypertension and left ventricular hypertrophy by determining the plasma concentration levels in carriers of different BNP gene variants.
Methods
The study involved 141 middle-aged male residents in Podillia region. Among them 62 men from the main group were diagnosed uncomplicated EH with LVH (stages 1 and 2), with saved systolic function and CHF I-II classes according to NYHA Classification, whose average age was 49,19±0,66 years and 79 healthy men whose age (49,01±0,73 years) did not differ from patients with uncomplicated EH with LVH and made the control group (p>0,05). The diagnosis of EH was established on the basis of the patients' complaints, anamnesis, physical examination, laboratory and instrumental methods of investigation according to the guideline of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) in 2013 [6] .
Systolic function of left ventricle was assessed in terms of ejection fraction (EF). Systolic function was considered saved when EF was over 45%. All patients during the examination were treated at Vinnytsia regional specialized dispensary of radiation protection of the Ministry of Health of Ukraine and Military Medical Center of the Central Region of Air Force of Ukraine and were observed from December 2013 to July 2014.
Exclusion criteria of the study were: secondary hypertension, renal and liver dysfunction, coronary heart disease the onset of which was before EH, endocrine, hematological, neoplastic and autoimmune disorders, patients with EH complications: myocardial infarction, acute cerebrovascular accident. Genotyping of the BNP gene was conducted using polymerase chain reaction after isolation of genomic DNA from white blood cells of venous blood. This study was carried out jointly with the Research Institute of the genetic and immunological bases of pathology and pharmacokinetics "Ukrainian Medical Stomatological Academy" (Poltava, the head is prof. I.P. Kaidashev). The BNP concentration in plasma was determined by using ELISA method on enzyme-linked immunosorbent analyzer "Numareader single» (Germany) at 450 nm and differential filter 630 nm. To determine the BNP plasma concentration a standard set of the firm «Peninsula laboratories Inc.» (USA) was used.
The mathematical processing was performed on a personal computer using a standard statistical package STATISTICA 6,0. There were checking distribution of genes polymorphisms frequencies in the population according to HardyWeinberg equilibrium law using a calculator gene expert to calculate the number of statistical parameters in the study "case-control" which using SNP (State Scientific Center of the Russian Federation "HosNYY genetics", gen-exp.ru). 
Results
It was established that in the male control group the frequency of the genotype T381T of the BNP gene was 18,9% (n=15), the genotype T381C -49,37% (n=39) and the genotype C381C -31,65% (n=25) (pCC-TT>0.05; pTC-CC> 0.05; pTC-TT≤0,05). The frequency of the T allele in male from the control group was 43.67%, the C allele -56.33% (p<0.05).
It was investigated that in patients from the main group dominanted the C allele and the genotype T381C, but there were no significant differences in carriage of the genotype variants of the BNP gene compared with those in the control group (p> 0,05) ( Figure 1) . Fig. 1 The distribution of the BNP gene genotypes frequencies and alleles in men citizens of Podillia region in the healthy patients and the patients with uncomplicated EH and LVH (%) Note: The difference is significant (p≤0,05) when compared to: * -the T381C genotype/the C allele within each group.
The odds ratio was calculated to assess the risk of development of uncomplicated EH with LVH in carriers of different BNP genotypes in men citizens of Podillia region, age 40-60 years. It was established that inherited the BNP gene variant was not associated with the risk of development of uncomplicated EH (for genotypes general model for imitation is not significant χ 2 =2,18; p=0,14; odds ratio OR <1; alleles multiplicative model for imitation is not significant χ 2 =2,23, p=0,33; odds ratio OR <1) after calculating the number of statistical parameters using the calculator gene expert.
The plasma BNP level in the control group was 21,74 ± 0,50 pg/ml. In patients with uncomplicated EH and LVH average concentration of plasma BNP was 77,40 ± 2,85 pg/ml and was significantly higher than in the control group (p <0,0001).
The next step was to determine the BNP plasma levels in men with uncomplicated EH and LVH with different stages of arterial hypertension (AH). It was determined that there was not significant difference in BNP plasma concentrations in different stages of hypertension in patients with uncomplicated EH and LVH (p>0,05) ( Table 1) . It was interesting to find the difference in concentrations BNP concentrations in carriers of various variants of the BNP gene. It was established a significant difference inconcentrationsConcentrations BNP plasma concentrations between carriers of the genotypes T381T, T381C and C381C of the BNP gene both in the control group and in the patients with uncomplicated EH and LVH (p<0,0001). The highest concentration of BNP was found in homozygote carriers of the genotype C381C of the BNP gene and the lowest level was found in homozygote carriers of the genotype T381T of the BNP gene (p <0,0001) and that means that the presence of the C allele in the genotype of the BNP gene is associated with a higher plasma concentration of the peptide (Table 2) . The BNP plasma levels was determinated in the healthy men and in the patients with uncomplicated EH and LVH in carriers of different alleles of the BNP gene. It was found that in the healthy men there was not significant difference in the BNP plasma levels in carriers of different alleles of the BNP gene (pT-C> 0,05). In the patients with uncomplicated EH and LVH was significantly greater level of BNP in carriers of the C allele of the BNP gene (pT-C <0,0001). However, the BNP plasma concentration in men with EH who are carriers of the C allele and the T allele of the BNP gene were significantly higher than in the same allele carriers in the control group (Table 3) . There were established BNP levels for screening diagnosis of uncomplicated EH with LVH in men citizens of Podillia region in Ukraine that can be applied during examining of large groups of people to identify persons who require to be conducted full examination including ultrasound of the heart and indentify the presence of EH:
-The BNP level ≥47,22 pg/ml (sensitivity -95%, specificity -82,2% correctness -89,23%, false negative answer -5%, false positive answer -11,82%) can diagnose uncomplicated EH with LVH in males.
However, the BNP plasma concentration can be influenced by genetics. The results indicated that the presence of the C allele in the genotype of the BNP gene is associated with higher plasma concentrations of peptide so it was decided to calculate the BNP boundary levels for the C allele carriers -carriers of the heterozygote genotype T381C and carriers of the homozygote genotype T381T:
-The BNP level ≥82,41 pg/ml (sensitivity -92%, specificity -84,7% correctness -84,14%, false negative answer -4%, false positive answer -9,56%) can diagnose uncomplicated EH with LVH in males the C allele carriers and the heterozygote T381C, C381C of the BNP gene;
-The BNP level ≥45,34 pg/ml (sensitivity -91%, specificity -84,3% correctness -96,1%, false negative answer -0%, false positive answer -5,26%) can diagnose uncomplicated EH with LVH in males with the homozygote genotype T381T of the BNP gene.
Discussion
It was determined that in both healthy men inhabitants of Podillia region and in patients with uncomplicated EH and LVH dominates the C allele and the genotype T381C of the BNP gene. At the same time the C381C genotype reveals more frequently in the Americans, the Russians and the Germans. The T381T genotype is more common among Russian citizens. The frequencies of polymorphic genotypes of the BNP gene did not differ significantly in patients from different populations [2, 7, 10] .
No significant differences were revealed in the BNP plasma levels in men with uncomplicated EH and LVH with different stages of hypertension. Different plasma peptide concentrations in patients with different genotypes of the BNP gene might cause some discussion. As noted above, the patients with uncomplicated EH and LVH have significantly higher peptide levels for all variants of genotypes of the BNP gene than the healthy men. Thus, the studies of ) found that inherited genotypes of the BNP gene with the presence of the C allele -T381C and C381C is associated with high plasma concentration of peptide in patients with uncomplicated EH and LVH [7, 13, 15] . E.N. Berezikova (2013) investigated the BNP gene polymorphism in patients of both sexes with CHF where it was shown that in healthy individuals of Russian population with the genotype C381C plasma levels of N-terminal prohormone of brain natriuretic peptide was significantly higher than in carriers of the genotype T381T [2] . BNP plasma concentrations in carriers of the C allele and the genotype -C381C and T381C were significantly higher than in carriers of the genotype T381T among the control group and the patients with uncomplicated EH and LVH which corresponded to literature data. This may require further in-depth research of genetic influence on the BNP plasma concentrations, along with other factors, which could require revision of normative BNP levels in healthy subjects and as pathological marker where BNP has diagnostic value.
Conclusions
1. The T381C genotype and the C allele of the BNP gene dominate among the healthy men and the patients with uncomplicated EH and LVH, residents of Podillia region, age 40-60 years. 2. The BNP gene variant is not associated with the risk of development of uncomplicated EH with LVH in men inhabitants of Podillia region in Ukraine. 3. The carriers of the genotypes C381C and T381C and the C allele of the BNP gene have significantly higher plasma levels of the aforementioned peptide among the control group and in the patients with uncomplicated EH and LVH. 4. There were estimated BNP boundary levels that can be used for screening of large contingents of people for early diagnosis of uncomplicated EH with LVH for the C allele and the heterozygote T381C and C381C carriers and homozygote carriers of the genotype T381T of the BNP gene.
